135 related articles for article (PubMed ID: 10516626)
1. Response-selective C5a agonists: differential effects on neutropenia and hypotension in the rat.
Short AJ; Paczkowski NJ; Vogen SM; Sanderson SD; Taylor SM
Br J Pharmacol; 1999 Oct; 128(3):511-4. PubMed ID: 10516626
[TBL] [Abstract][Full Text] [Related]
2. Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity.
Finch AM; Vogen SM; Sherman SA; Kirnarsky L; Taylor SM; Sanderson SD
J Med Chem; 1997 Mar; 40(6):877-84. PubMed ID: 9083476
[TBL] [Abstract][Full Text] [Related]
3. Differential activities of decapeptide agonists of human C5a: the conformational effects of backbone N-methylation.
Vogen SM; Paczkowski NJ; Kirnarsky L; Short A; Whitmore JB; Sherman SA; Taylor SM; Sanderson SD
Int Immunopharmacol; 2001 Nov; 1(12):2151-62. PubMed ID: 11710544
[TBL] [Abstract][Full Text] [Related]
4. The influence of Lys68 in decepeptide agonists of C5a on C5a receptor binding, activation and selectivity.
Vogen SM; Finch AM; Wadi SK; Thatcher J; Monk PN; Taylor SM; Sanderson SD
J Pept Res; 1999 Jan; 53(1):8-17. PubMed ID: 10195437
[TBL] [Abstract][Full Text] [Related]
5. Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes.
Woodruff TM; Strachan AJ; Sanderson SD; Monk PN; Wong AK; Fairlie DP; Taylor SM
Inflammation; 2001 Jun; 25(3):171-7. PubMed ID: 11403208
[TBL] [Abstract][Full Text] [Related]
6. Antagonistic peptides against human anaphylatoxin C5a.
Kaneko Y; Okada N; Baranyi L; Azuma T; Okada H
Immunology; 1995 Sep; 86(1):149-54. PubMed ID: 7590876
[TBL] [Abstract][Full Text] [Related]
7. Novel C5a receptor antagonists regulate neutrophil functions in vitro and in vivo.
Pellas TC; Boyar W; van Oostrum J; Wasvary J; Fryer LR; Pastor G; Sills M; Braunwalder A; Yarwood DR; Kramer R; Kimble E; Hadala J; Haston W; Moreira-Ludewig R; Uziel-Fusi S; Peters P; Bill K; Wennogle LP
J Immunol; 1998 Jun; 160(11):5616-21. PubMed ID: 9605167
[TBL] [Abstract][Full Text] [Related]
8. Direct binding of a fragment of the Wiskott-Aldrich syndrome protein to the C-terminal end of the anaphylatoxin C5a receptor.
Tardif M; Brouchon L; Rabiet MJ; Boulay F
Biochem J; 2003 Jun; 372(Pt 2):453-63. PubMed ID: 12600272
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of the C5a receptor on the main cell types of rat liver as demonstrated with a novel monoclonal antibody and by C5a anaphylatoxin-induced Ca2+ release.
Schlaf G; Schieferdecker HL; Rothermel E; Jungermann K; Götze O
Lab Invest; 1999 Oct; 79(10):1287-97. PubMed ID: 10532591
[TBL] [Abstract][Full Text] [Related]
10. Anaphylatoxin receptor promiscuity for commonly used complement C5a peptide agonists.
Li XX; Clark RJ; Woodruff TM
Int Immunopharmacol; 2021 Nov; 100():108074. PubMed ID: 34454293
[TBL] [Abstract][Full Text] [Related]
11. Receptors for the anaphylatoxin C5a (CD88) on human mesangial cells.
Wilmer WA; Kaumaya PT; Ember JA; Cosio FG
J Immunol; 1998 Jun; 160(11):5646-52. PubMed ID: 9605171
[TBL] [Abstract][Full Text] [Related]
12. [Small increase of CR1 and CR3 by C5a-receptors on polymorphonuclear leukocytes in systemic lupus erythematosus].
Doi T; Takemura S; Onodera H; Ueda M; Deguchi M; Nakahara R; Ichio N; Nakanishi S; Seto N; Yanagida K; Kondo M
Arerugi; 1997 Nov; 46(11):1108-13. PubMed ID: 9436327
[TBL] [Abstract][Full Text] [Related]
13. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity.
March DR; Proctor LM; Stoermer MJ; Sbaglia R; Abbenante G; Reid RC; Woodruff TM; Wadi K; Paczkowski N; Tyndall JD; Taylor SM; Fairlie DP
Mol Pharmacol; 2004 Apr; 65(4):868-79. PubMed ID: 15044616
[TBL] [Abstract][Full Text] [Related]
14. Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat.
Short A; Wong AK; Finch AM; Haaima G; Shiels IA; Fairlie DP; Taylor SM
Br J Pharmacol; 1999 Feb; 126(3):551-4. PubMed ID: 10188960
[TBL] [Abstract][Full Text] [Related]
15. Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury.
Heller T; Hennecke M; Baumann U; Gessner JE; zu Vilsendorf AM; Baensch M; Boulay F; Kola A; Klos A; Bautsch W; Köhl J
J Immunol; 1999 Jul; 163(2):985-94. PubMed ID: 10395696
[TBL] [Abstract][Full Text] [Related]
16. C5a receptor and thymocyte apoptosis in sepsis.
Riedemann NC; Guo RF; Laudes IJ; Keller K; Sarma VJ; Padgaonkar V; Zetoune FS; Ward PA
FASEB J; 2002 Jun; 16(8):887-8. PubMed ID: 12039868
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a.
Finch AM; Wong AK; Paczkowski NJ; Wadi SK; Craik DJ; Fairlie DP; Taylor SM
J Med Chem; 1999 Jun; 42(11):1965-74. PubMed ID: 10354404
[TBL] [Abstract][Full Text] [Related]
18. Human T cells express the C5a receptor and are chemoattracted to C5a.
Nataf S; Davoust N; Ames RS; Barnum SR
J Immunol; 1999 Apr; 162(7):4018-23. PubMed ID: 10201923
[TBL] [Abstract][Full Text] [Related]
19. Development of C5a receptor antagonists. Differential loss of functional responses.
Konteatis ZD; Siciliano SJ; Van Riper G; Molineaux CJ; Pandya S; Fischer P; Rosen H; Mumford RA; Springer MS
J Immunol; 1994 Nov; 153(9):4200-5. PubMed ID: 7930622
[TBL] [Abstract][Full Text] [Related]
20. Expression of an epitope tagged human C5a receptor and antibody-mediated immobilization of detergent-solubilized receptor for drug discovery screening.
Sloan DD; Barrett RW; Tate EH; England BP
Protein Expr Purif; 1997 Oct; 11(1):119-24. PubMed ID: 9325147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
